PB022

PB022 is a biosimilar monoclonal antibody currently in early-stage development by Polpharma Biologics Group for the treatment of asthma. It is in the cell line development and preclinical phase, targeting inflammatory pathways associated with respiratory and immune system diseases. As a biosimilar, PB022 is designed to be highly similar to an already approved reference biologic medication, although the specific identity of the reference product and the molecular target of PB022 have not been publicly disclosed by the developer. Polpharma Biologics, an international biotechnology company based in the European Union, focuses on the integrated development and manufacturing of biosimilar medicines, with PB022 representing one of their early-stage pipeline candidates in the immunology and respiratory space.